Abstract
Natalizumab (Tysabri) is a relatively new biological monoclonal antibody to α4β1 integrin, a molecule important in the mobilisation of lymphocytes and other non-neutrophil leukocytes from the circulation into the brain. It is available as treatment for relapsing remitting MS since autumn last year and the number of patients is steadily increasing. Despite its effectiveness, it is usually used as second line treatment due to several reports of Progressive Multifocal Leukoencephalopathy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
